Dr Cusnir presents the highlights of the significant findings in gastrointestinal GL tumors, focusing on four key studies.

It reviews the Checkmate 557 study on nivolumab's role after chemoradiation in esophageal cancers. The Matterhorn study shows durvalumab's impact on survival rates. It also discusses treatments for HER2 positive patients, including trastuzumab Deruxtecan.

Future research aims to ensure equitable benefits and explore new targeted therapies to enhance patient outcomes.